PE20060400A1 - Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublima - Google Patents

Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublima

Info

Publication number
PE20060400A1
PE20060400A1 PE2005000439A PE2005000439A PE20060400A1 PE 20060400 A1 PE20060400 A1 PE 20060400A1 PE 2005000439 A PE2005000439 A PE 2005000439A PE 2005000439 A PE2005000439 A PE 2005000439A PE 20060400 A1 PE20060400 A1 PE 20060400A1
Authority
PE
Peru
Prior art keywords
mirtazapine
pharmaceutical formulation
sublimating
acid
salt
Prior art date
Application number
PE2005000439A
Other languages
English (en)
Inventor
Sytske Hyke Moolenaar
Gerardus Johannes Kemperman
Der Voort Maarschalk Kees Van
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20060400A1 publication Critical patent/PE20060400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA QUE COMPRENDE UN ENANTIOMERO S DE MIRTAZAPINA, CARACTERIZADA PORQUE LA MIRTAZAPINA SE ENCUENTRA BAJO LA FORMA DE UNA SAL SOLIDA SELECCIONADA DE: SAL DE ACIDO MALEICO, ACIDO BROMHIDRICO, ACIDO FUMARICO Y ACIDO METANOSULFONICO, Y DONDE DICHA SAL SOLIDA NO SUBLIMA. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION
PE2005000439A 2004-04-21 2005-04-20 Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublima PE20060400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04101664 2004-04-21

Publications (1)

Publication Number Publication Date
PE20060400A1 true PE20060400A1 (es) 2006-05-27

Family

ID=34928990

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000439A PE20060400A1 (es) 2004-04-21 2005-04-20 Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublima

Country Status (31)

Country Link
US (1) US20070111993A1 (es)
EP (1) EP1729777B1 (es)
JP (2) JP5260959B2 (es)
CN (2) CN101824035A (es)
AR (1) AR049028A1 (es)
AT (1) ATE424210T1 (es)
AU (1) AU2005235383B2 (es)
BR (1) BRPI0509953A (es)
CA (1) CA2561281C (es)
CY (1) CY1109018T1 (es)
DE (1) DE602005013066D1 (es)
DK (1) DK1729777T3 (es)
EC (1) ECSP066938A (es)
ES (1) ES2321961T3 (es)
HR (1) HRP20090190T1 (es)
IL (1) IL178201A (es)
LV (1) LV13556B (es)
MX (1) MXPA06011830A (es)
MY (1) MY144899A (es)
NO (1) NO20065077L (es)
NZ (1) NZ550052A (es)
PE (1) PE20060400A1 (es)
PL (1) PL1729777T3 (es)
PT (1) PT1729777E (es)
RS (1) RS50764B (es)
RU (1) RU2375362C2 (es)
SI (1) SI1729777T1 (es)
TW (1) TW200538100A (es)
UA (1) UA89773C2 (es)
WO (1) WO2005102352A1 (es)
ZA (1) ZA200608305B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83666C2 (ru) * 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
EP1792618A1 (en) * 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
TW200808804A (en) * 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
PL3261645T3 (pl) 2015-02-27 2021-12-06 Dechra Limited Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów
CN111053735A (zh) * 2020-02-25 2020-04-24 上海阶平医院管理有限公司 一种治疗失眠的冷敷凝胶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4193828A (en) * 1976-07-27 1980-03-18 Fiber Materials, Inc. Method of forming carbon composites
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
WO1999051237A1 (en) * 1998-04-02 1999-10-14 Akzo Nobel N.V. Oral liquid antidepressant solution
WO2001000196A2 (en) * 1999-06-25 2001-01-04 University Of South Florida Mirtazapine for weight gain in wasting diseases
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU6474200A (en) * 1999-12-13 2001-06-18 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound
EP1242092B1 (en) * 2000-04-05 2003-07-02 Akzo Nobel N.V. Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug

Also Published As

Publication number Publication date
IL178201A0 (en) 2006-12-31
CA2561281A1 (en) 2005-11-03
AR049028A1 (es) 2006-06-21
IL178201A (en) 2010-06-30
WO2005102352A1 (en) 2005-11-03
EP1729777A1 (en) 2006-12-13
AU2005235383B2 (en) 2010-05-27
PT1729777E (pt) 2009-04-27
US20070111993A1 (en) 2007-05-17
HRP20090190T1 (en) 2009-05-31
CN1942191B (zh) 2011-02-02
MXPA06011830A (es) 2007-03-23
JP2007533705A (ja) 2007-11-22
CA2561281C (en) 2013-04-02
CN101824035A (zh) 2010-09-08
ECSP066938A (es) 2006-12-20
ES2321961T3 (es) 2009-06-15
DE602005013066D1 (de) 2009-04-16
JP2013136626A (ja) 2013-07-11
RS50764B (sr) 2010-08-31
TW200538100A (en) 2005-12-01
CN1942191A (zh) 2007-04-04
SI1729777T1 (sl) 2009-08-31
BRPI0509953A (pt) 2007-09-25
UA89773C2 (ru) 2010-03-10
RU2375362C2 (ru) 2009-12-10
JP5260959B2 (ja) 2013-08-14
ZA200608305B (en) 2008-08-27
LV13556B (en) 2007-07-20
NO20065077L (no) 2006-11-14
AU2005235383A1 (en) 2005-11-03
ATE424210T1 (de) 2009-03-15
MY144899A (en) 2011-11-30
PL1729777T3 (pl) 2009-07-31
CY1109018T1 (el) 2014-07-02
EP1729777B1 (en) 2009-03-04
NZ550052A (en) 2010-02-26
RU2006140988A (ru) 2008-05-27
DK1729777T3 (da) 2009-06-08

Similar Documents

Publication Publication Date Title
CL2011002194A1 (es) Formulacion que comprende anticuerpo en un regulador de histidina-arginina ph 4.5 a 6.5; articulo de manufactura que comprende dicha formulacion; metodo para estabilizar un anticuerpo en una formulacion farmaceutica acuosa.
PE20060400A1 (es) Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublima
EA201491675A1 (ru) Новые вещества
CL2017003445A1 (es) Formas solidas y formulaciones de compuestos de imidazopirazina.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
AR054511A1 (es) Una composicion que comprende emtricitabina y tenofovir df granuladas en seco
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
EA200800168A1 (ru) Гидрохлориды и гидраты 1-[(3-цианопиридин-2-ил)метил]-3-метил-7-(2-бутин-1-ил)-8-(3-аминопиперидин-1-ил)ксантина, их получение и их применение в качестве лекарственных средств
EA201100969A1 (ru) Солевые формы органического соединения
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
CL2012001329A1 (es) Procedimiento de purificacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo-[3,4-b]piridin-3-il] pirimidin-5-il} metilcarbamato de metilo; y el compuesto intermediario que se obtiene.
ECSP10010295A (es) Formulacion de anticuerpo
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
CL2009001252A1 (es) Preparacion alimenticia que produce una sensacion de cosquilleo o quemante que comprende acido acilamino o una sal de el usos.
EA200970851A1 (ru) Еженедельное введение ингибиторов дипептидилпептидазы
DOP2011000329A (es) Preparacion de solido
ECSP10010588A (es) Formulacion de medicamento solida con liberacion retardada
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
HK1105192A1 (en) Method of yielding hypobromous acid in aqueous system
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
CR11476A (es) Granulacion en humedo utilizando un agente secuestrante de agua
CO6410282A2 (es) Formulaciones orales sólidas de una pirido-pirimidinona

Legal Events

Date Code Title Description
FC Refusal